“Safety and Efficacy of Posttransplant Cyclophosphamide with Tacrolimus and Mycophenolate Mofetil in HLA-Matched and Mismatched Peripheral Blood Stem Cell Transplantation”

https://pubmed.ncbi.nlm.nih.gov/38114645

The study found that posttransplant cyclophosphamide (PTCy) with tacrolimus and mycophenolate mofetil as graft-versus-host disease (GVHD) prophylaxis was safe and effective in both HLA-matched and HLA 1-2 allele mismatched peripheral blood stem cell transplantation, resulting in low rates of acute and chronic GVHD and high survival rates.